RUDIVAX LIVE ATTENUATED RUBELLA VACCINE 1000 DICC50 / 0.5ml lyophilisate+solvent for injection suspension medication leaflet

J07BJ01 • live attenuated rubella vaccine • Antiinfectives for systemic use | Viral vaccines | Rubella vaccines

The live attenuated rubella vaccine is used to prevent rubella, a contagious viral disease caused by the rubella virus. The vaccine contains a weakened form of the virus, which stimulates the immune system to produce specific antibodies against it, providing long-term protection against infection.

The vaccine is administered subcutaneously, usually in two doses, with the first dose given at 12-15 months of age and the second between 4 and 6 years. It is recommended for children and adults who have not been previously vaccinated or have not had rubella.

Common side effects include fever, rashes, pain, or swelling at the injection site. In rare cases, severe adverse reactions such as allergic reactions or transient arthralgia may occur.

The live attenuated rubella vaccine is an essential preventive measure for reducing the incidence of rubella and its associated complications, such as congenital rubella syndrome in pregnant women.